Sorry, the best answer is C. According to the reference, A is incorrect because 47% of individuals switching to this regimen had viremia at baseline (Viral suppression doubled to 94% with the use of CAB + LEN). While depressive disorders in choice B is described as a Warning and Precaution in the package labeling for Cabenuva, it is more specifically associated with the rilpivirine component. This reason is not listed as any justification for using this LAI combination of CAB + LEN. D is incorrect because only 1 patient in the reference was switched to this CAB/LEN due to high BMI.
Reference: Gandhi M, et al. OFID, 2024
https://academic.oup.com/ofid/article/11/4/ofae125/7646382 doi: 10.1093/ofid/ofae125